Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
The Socialist Party of Albania emerged in the aftermath of the fall of communism in Albania that had dominated Albanian politics since the end of World War II. The dissolution of the People's Socialist Republic prompted a reevaluation of political ideologies and a quest for democratic governance, paving the way for the rise of multiple political entities. The roots of the Socialist Party can be traced back to the Party of Labour of Albania under its founder Enver Hoxha, which had been the ruling party for over four decades. Hoxha's successor Ramiz Alia was forced to introduce limited reforms in the late 1980s. On 11 December 1990, Alia announced that the PPSh had given up its monopoly of power. The PPSh won the 1991 Albanian Constitutional Assembly election, the first free elections held in the country in almost 80 years. By this time, it was no longer a Marxist–Leninist party. At an extraordinary congress on 10–13 June 1991, the PPSh reorganized as the PS in an effort to adapt to survive in the new system. Fatos Nano, a man from the intelligentsia, was elected the new chairman. Nano helped to reform the old Communist party and made it a member of the Socialist International. A faction of the party, led by Ilir Meta, split away from the PS in 2004 and formed the Socialist Movement for Integration (Lëvizja Socialiste për Integrim, LSI). On 10 October 2005, Nano resigned as the chairman of the PS after losing the 2005 Albanian parliamentary election, and was succeeded by Edi Rama.
Cardiovascular diseases, which include diseases of the heart, are the leading cause of death worldwide. The majority of cardiovascular disease is noncommunicable and related to lifestyle and other factors, becoming more prevalent with ageing. An estimated 19.8 million people died of cardiovascular disease in 2022, around 32% of all deaths globally. This rate varies from a lower 28% to a high 40% in high-income countries. Doctors that specialise in the heart are called cardiologists. Many other medical professionals are involved in treating diseases of the heart, including doctors, cardiothoracic surgeons, intensivists, and allied health practitioners including physiotherapists and dieticians.
=== Empirical methods === A set of empirical rules relating the protein structure to the pKa values of ionizable residues have been developed by Li, Robertson, and Jensen. These rules form the basis for the web-accessible program called PROPKA for rapid predictions of pKa values. A recent empirical pKa prediction program was released by Tan KP et.al. with the online server DEPTH web server.
Sources: en.wikipedia.org
== History == OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954. It was introduced for medical use by 1957. OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed.
Irresponsibility on the part of the radioactive material's owners, usually a hospital, university, or military, and the absence of regulation concerning radioactive waste, or a lack of enforcement of such regulations, have been significant factors in radiation exposures. For an example of an accident involving radioactive scrap originating from a hospital, see the Goiânia accident. Transportation accidents involving spent nuclear fuel from power plants are unlikely to have serious consequences due to the strength of the spent nuclear fuel shipping casks. On 15 December 2011, top government spokesman Osamu Fujimura of the Japanese government admitted that nuclear substances were found in the waste of Japanese nuclear facilities. Although Japan did commit itself in 1977 to inspections in the safeguard agreement with the IAEA, the reports were kept secret for the inspectors of the International Atomic Energy Agency. Japan did start discussions with the IAEA about the large quantities of enriched uranium and plutonium that were discovered in nuclear waste cleared away by Japanese nuclear operators. At the press conference Fujimura said: "Based on investigations so far, most nuclear substances have been properly managed as waste, and from that perspective, there is no problem in safety management," but according to him, the matter was at that moment still being investigated.
Insulin detemir is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects last for up to 24 hours. Common side effects include (hypoglycemia, allergic reactions, pain at the injection site, and weight gain. It appears to be safe for use during pregnancy and breastfeeding. Insulin detemir works by increasing the amount of glucose absorbed by tissues and reducing the amount of glucose produced by the liver. Insulin detemir was approved for medical use in the European Union in June 2004 and in the United States in June 2005. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it was the 127th most commonly prescribed medication in the United States, with over 4 million prescriptions. Insulin detemir is only sold under the name Levemir by Novo Nordisk, who owned its patent until 2019. in certain countries, Levemir and certain related products were discontinued in 2024.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.